Linda Giering, PhD
*Medical Writer, Matawan, New Jersey
Address correspondence to: Linda Giering, PhD. Email: email@example.com.
Disclosure statement: The author reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Lung cancer is the second most common form of noncutaneous cancer and is the leading cause of death in men and women. The National Lung Screening Trial (NLST) showed that annual screening with low-dose computed tomography in high-risk populations reduced mortality by 15% to 20%. Based on the results of this trial, the US Preventative Services Task Force recommended lung cancer screening in high-risk men and women. Following this recommendation, the Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination in early 2015 supporting annual lung cancer screening with low-dose CT (LDCT) based on the NLST criteria. Screening is a strategy used in a population to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms. Although LDCT can detect lung cancer early, an important benefit, it can also result in potential harms including false-positive results, overdiagnosis, and unnecessary radiation exposure. This review focuses on the pros and cons of LDCT lung cancer screening and important considerations when implementing a lung cancer screening program.
* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.
Enter your email address to receive our new course alerts.